A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | MicrobiomeTrials
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-08-27Est. Completion: 2027-11
Enrollment target: 375 participants
Locations
Cancer Research SA, Adelaide, Australia
Monash Medical Centre, Clayton, Australia
Peter MacCallum Cancer Centre, Melbourne, Australia
The Alfred Hospital, Melbourne, Australia
One Clinical Research, Nedlands, Australia
Scientia Clinical Research Limited, Randwick, Australia
Beijing Cancer Hospital, Beijing, China
Anhui Provincial Hospital, Hefei, China
First Affiliated Hospital of Xinxiang Medical University, Henan, China
Hunan Province Cancer Hospital, Hunan, China
Shandong University-Jinan Central Hospital, Shandong, China
Qilu Hospital of Shandong University', Shandong, China
Linyi Tumor Hospital, Shandong, China
Shanghai East Hospital, Shanghai, China
Shanghai GoBroad Cancer Hospital, Shanghai, China
Sichuan Cancer Hospital, Sichuan, China
Zhejiang Cancer Hospital, Zhejiang, China
Other microbiome trials you might be interested in